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Drug delivery across length scales  22 
Over the last century there has been a dramatic change in the nature of 23 
therapeutic, biologically active molecules available to treat disease.  Therapies 24 
have evolved from extracted natural products towards rationally designed 25 
biomolecules, including small molecules, engineered proteins, and nucleic acids. 26 
The use of potent drugs which target specific organs, cells, or biochemical 27 
pathways, necessitates new tools which can enable controlled delivery and dosing 28 
of these therapeutics to their biological targets. Here, we review the 29 
miniaturisation of drug delivery systems from the macro- to nano- scale, focusing 30 
on controlled dosing and controlled targeting as two key parameters in drug 31 
delivery device design. We describe how the miniaturisation of these devices 32 
enables the move from repeated, systemic dosing, to on demand, targeted 33 
delivery of therapeutic drugs, and highlight areas of focus for the future. 34 
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INTRODUCTION 38 
Over the last century there has been a dramatic change in the nature of therapeutic, 39 
biologically active molecules available to treat disease. This is represented by the move 40 
from extracted natural products and synthesised natural product mimics1, towards 41 
rationally designed biomolecules including small molecules, engineered proteins, and 42 
nucleic acids2-4. The evolution of potent drugs which target specific organs, cells, or 43 
biochemical pathways, necessitates new tools which can enable controlled delivery and 44 
dosing of these therapeutics to their biological targets. Therapies which can be 45 
administered as a single procedure, either through the delivery of a single dose of a 46 
potent curative therapeutic, or through the implantation of a device that can maintain a 47 
precise, long term drug dosing regime, are highly desired.  48 
Macro-scale drug delivery devices have been widely adopted since the 1970s, 49 
when long-acting intra-uterine contraceptive implants were offered as an alternative to 50 
daily repeated oral administration of systemically released hormones5. These implants 51 
could be inserted during a single procedure, and remained effective for several years 52 
through localised and controlled release of contraceptive hormones. Since then, a wide 53 
range of systems for therapeutic drug delivery have been developed, broadly focused on 54 
systems which can help to regulate drug dosing6, and those which aid targeted delivery 55 
for site-specific therapeutic action7-10. Drug delivery devices are in widespread clinical 56 
use, however, many of these systems are limited in their ability to deliver therapeutics 57 
to smaller biological structures with control over both drug dosing and therapeutic 58 
targeting.   59 
For certain drugs, failure to adhere to a specific dosing schedule can 60 
dramatically impact therapeutic efficacy. In vaccination, the timing of drug dosing (e.g. 61 
  
the dosing regimen as well as the time of day) is an important parameter in the 62 
development of robust immunity11. Drug dosing is therefore a crucial consideration in 63 
drug delivery device design, and many strategies have been explored to regulate dosing; 64 
including continuous, controlled release systems7, 12-15, enhanced therapeutic circulation 65 
time16, 17 and stimuli responsive drug administration7, 18-22. Separately, as therapeutic 66 
targets become increasingly specific, and therapies become increasingly potent, 67 
delivering site specific therapeutic action becomes a more critical design feature. 68 
Control over both of these aspects can improve patient safety, quality of life and 69 
compliance by lessening the stringent requirements of strict medication schedules and 70 
reducing off-target effects.   71 
Here, we review drug delivery systems across the macro- to nano- scale, 72 
highlighting systems which enable controlled dosing, and those which aid drug 73 
targeting. We explore the role of length scale in the function of these systems, 74 
considering macro-, micro- and nano- systems which are capable of delivery to organs, 75 
cells and cellular substructures of interest (Figure 1). We describe how the 76 
miniaturisation of these devices enables the move from repeated, systemic dosing, to on 77 
demand, targeted delivery of therapeutic drugs, and consider areas of future interest.  78 
MACRO SCALE DELIVERY SYSTEMS   79 
Macro scale delivery systems, measuring from 1 mm upwards in size, are particularly 80 
suited for long-term drug delivery. Their scale allows a single device to contain a 81 
considerable therapeutic reservoir, and enables precise engineering of accompanying 82 
parts required for more complex controlled drug administration, such as pumps, 83 
batteries, catheters and sensors23, 24. For effective systemic drug delivery, drugs must 84 
first traverse the body’s natural physical barriers and reach the systemic circulation, 85 
  
which can prove challenging for macro scale devices25. A number of approaches have 86 
been used to address this challenge, with examples including ingestible devices26-28, 87 
topical delivery through transdermal systems29-32, controlled release implants inserted 88 
close to vasculature6, and infusion pump systems which are connected to the systemic 89 
circulatory system via cannula or catheter23. Here, we review a range of macro scale 90 
drug delivery devices, and discuss how their scale impacts their ability to deliver 91 
therapeutics.     92 
Systemic delivery systems 93 
Ingestible devices 94 
Ingestion is one of the most convenient administration routes for devices small enough to 95 
pass through the oesophagus25. Although a widely used drug delivery route, ingestion 96 
based delivery mechanisms have typically had limited usefulness in long term and 97 
controlled delivery systems, due to frequent gastric emptying times of between 2-3 98 
hours33. To combat this, several approaches have been developed to improve gastric 99 
retention times for macro devices small enough to swallow. These approaches focus on 100 
retaining devices within the stomach to provide continuous, systemic drug release, 101 
through adhesion to the stomach wall or changes in device geometry. In one example, 102 
macro devices composed of drug eluting polymers can be folded into a capsule small 103 
enough to swallow, which then expands in the stomach. These low density, floating 104 
devices are buoyant, and cannot pass through the pyloric sphincter and into the intestines 105 
intact28, 33-35. Inclusion of a biodegradable moiety allows the devices to slowly degrade in 106 
vivo, and subsequently passage through the gastro intestinal tract post drug delivery. 107 
Advances in device design will enable systems to be retained beyond the current limit of 108 
a few months, potentially allowing longer term macro scale delivery systems which can 109 
  
be administered without surgical intervention.  Although ingestible devices offer a robust 110 
controlled delivery system that can passage through the gastro intestinal (GI) system, 111 
orally delivered drugs must first be absorbed through the gut to become bioavailable. The 112 
GI tract consists of the stomach, small intestine (duodenum, jejunum and ileum), the large 113 
intestine (colon), and the rectum; drug absorption can occur across the entire GI tract. The 114 
majority of drug absorption is occurs via the highly adapted microvilli in the small 115 
intestine, however class III/IV drugs have been shown to preferentially absorb across the 116 
colon36.  Several drug delivery systems utilise the distinct chemical environments present 117 
in specific regions of the gastrointestinal tract to facilitate a more targeted drug delivery 118 
approach, discussed in detail in the targeted delivery section below. Regardless of 119 
absorption site, orally administered drugs are subject to first-pass metabolism and hepatic 120 
clearance, and so systemic bioavailability of a therapeutic drug concentration may be 121 
lower when compared to intravenous administration.  122 
Transdermal delivery 123 
In contrast to ingestible devices, transdermal drug delivery methods offer many benefits 124 
over the more traditionally administered oral route37. Firstly, compared to orally 125 
delivered pharmacologics of the same dose, they can provide increased levels of 126 
circulating, bioavailable drugs. This leads to a reduction in the drug dose needed to 127 
elicit a specific pharmacological effect38-40, and can therefore reduce side effects. 128 
Transdermal patches provide a controlled release system which is well suited to the 129 
delivery of small molecules, though dermal penetration and delivery efficacy is affected 130 
by both the molecular size and hydrophilicity of the therapeutic being administered. 131 
Transdermal patches have been widely used to deliver small molecules  such as nicotine 132 
in smoking cessation therapies41, and contraceptive/postmenopausal hormones such as 133 
estradiol and estrone38. Drug delivery patches are well suited for the continuous, 134 
  
systemic delivery of low dose therapeutics. Drug delivery profiles range from a few 135 
days to a few weeks due to limitations in drug loading capacity, and patches must 136 
remain attached to the skin for the duration of delivery.  137 
Polymer implants  138 
Implantable polymer devices have been in use since the 1970’s for longer term systemic 139 
drug delivery. Early examples included the Norplant® and Jadelle® non-degradable 140 
subcutaneous contraceptive implants, which provided controlled release of 141 
contraceptive hormones over 5 years. Early devices were composed of an implanted 142 
polymer-drug composite coated with a porous ethyl vinyl acetate membrane42-44. This 143 
membrane facilitated controlled kinetic release of the hormones, and similar devices 144 
have been used to systemically deliver a range of pharmaceuticals including anti-145 
inflammatory drugs and antibiotics45-48. As with the early Norplant® devices, many of 146 
these systems are based on non-degradable polymers with a fixed-rate delivery profile, 147 
controlled by drug diffusion from within the device. Devices are usually implanted, and 148 
removed, via a minor surgical procedure at the end of their delivery lifetimes. To 149 
minimise surgical intervention required in the removal of these devices, longer-acting, 150 
degradable subcutaneous rod implants are currently in development49.   151 
In a similar approach, polymer hydrogel systems can be used for kinetically 152 
controlled systemic drug release7, 13, 50. Hydrogels have the potential to deliver virtually 153 
any therapeutic13, 51;  controlled release parameters are widely tuneable, with the nature 154 
of the hydrogel crosslinking determining the kinetics of controlled release and the 155 
biodegradability of the system. Both chemical (covalent) and physical (electrostatic 156 
assembly, stereo-complexation, supramolecular host-guest inclusion) crosslinking can 157 
be used to form hydrogel structures, however care must be taken to ensure the 158 
crosslinking agent does not impact drug potency. The wide range of cross-linking 159 
  
chemistries and polymer compositions provides tuneable delivery profiles that can last 160 
from several days up to several years, making polymer implants a versatile class of 161 
materials for drug delivery.  162 
Pump systems 163 
A number of implantable infusion pump systems have been developed for long-term 164 
delivery of therapeutics with metered dosing23.  These devices can measure up to 10 cm 165 
in diameter, and are often surgically implanted into patients. They generally consist of a 166 
reservoir-pump system which offers dosing schedules based on continuous fixed rate 167 
delivery, timed dose delivery, or on-demand delivery in response to specific stimuli. 168 
Dosing is usually controlled by an integrated pump system, which can be driven 169 
through mechanical, peristaltic means52-55, propellant systems56-59, or is driven by 170 
osmosis/diffusion60.  Due to the invasive surgical nature of implantation, these devices 171 
are primarily used for continuous therapeutic release in chronic medical conditions54, 56, 172 
57. Examples include intrathecal delivery of opioid based analgesic therapies, or delivery 173 
of muscle relaxants such as baclofen in patients with severe contractions. This 174 
continuous, metered dosing is particularly useful for analgesics in long term and 175 
palliative care, where the risk of misadministration and accidental overdose, a current 176 
concern with prescribed opioid tablets, can be reduced.   177 
For metered and on-demand dosing, stimuli responsive pumps can be used.  178 
These have proven particularly useful in diabetes, where sensors implanted under the 179 
skin can monitor and respond to glucose levels (MiniMed, Paradigm® Revel™)61. In 180 
these systems, reservoirs containing insulin, or twin reservoirs containing insulin and 181 
glucagon, are connected to sensors and facilitate metered drug delivery in response to 182 
hypo- or hyper-glycaemic events. Recently, wireless, smartphone connected sensors 183 
  
have been developed which allow patients and healthcare professionals to manage 184 
glucose levels in real time62, 63. These devices enable a truly patient specific, on-demand 185 
therapy, and are now clinically used in systemic applications60, 62, 64. However, the 186 
reservoir-based systems described limits the drug formulations to liquid systems, and 187 
device lifetimes are limited by the reservoir loading capacity. Additionally, the use of a 188 
power source to run the pumps in peristaltic devices limits the usefulness of these 189 
devices due to short battery lifetimes (usually limited to 4-7 years)65. Finally, due to 190 
their scale these more complex systems currently remain unsuitable for targeted or 191 
localised delivery approaches, which require smaller scale devices.  192 
Localised delivery systems 193 
Proximal polymer implants 194 
Many smaller macro scale devices can be surgically implanted within target organs to 195 
allow for proximal drug release, enabling therapeutic efficacy using lower doses than 196 
required in systemic delivery systems.  A widespread example are contraceptive devices 197 
introduced into the body via the vaginal tract. Contraceptive devices, briefly discussed 198 
earlier, are widely adopted clinically, and intra uterine devices (IUDs)5 have been in 199 
widespread use since the 1970s. IUDs and contraceptive vaginal rings can both be 200 
applied via a minor surgical procedure, and systems such as the NuvaRing® and 201 
Nestorone® offer controlled release on the order of 1 month to 3 years66, 67 before 202 
removal. For increased efficacy and reduced side effects,  new progestin-infused rings 203 
or combination drug devices that include both progesterone and estrogenic steroids are 204 
in development66. Future developments are focused on combining localised 205 
contraceptive drug release with systemic drug release, providing a multiplexed system 206 
to  reduce the risk of sexually transmitted infections67, 68 in a vaginal ring device.  207 
  
To reach less accessible target organs, surgical intervention is often required to 208 
position macro devices correctly. A number of polymer-based macro devices are 209 
indicated for controlled drug delivery to target organs, exemplified by stent-based69 210 
drug delivery. Stents are used for drug delivery in coronary interventions, and 211 
additionally in non-vascular target organs including the oesophagus, biliary duct, 212 
trachea, bronchi, sinus cavities, ureters, and urethra70, 71. First-generation vascular stents 213 
were approved by the FDA in 1994, and were manufactured from bare metal alloys or 214 
ceramic composites. However, these stents caused complications including hyperplastic 215 
growth and restenosis. Next generation stents therefore included novel metallic and 216 
polymeric stent materials with more open mesh-like frameworks, and simultaneously 217 
eluted anti-inflammatory drugs71, 72 to reduce restenosis. Stents often provide a physical 218 
support coupled with drug eluting capabilities. The continued optimisation of stent 219 
structures to reduce plaque prolapse (through increased radial strength) and increase 220 
biocompatibility (using fluoropolymer materials) renders these devices as versatile tools 221 
for the delivery of a diverse class of drugs. Many systems have been developed for the 222 
controlled delivery of anti-inflammatory, antimicrobial, and analgesic drugs70, 71 using 223 
diffusion based release profiles.  224 
In contrast, less rigid polymer systems, have been used for non-structural drug 225 
delivery. Both biodegradable polymer stents, and implantable hydrogel systems can be 226 
used for localised therapeutic delivery. Biodegradable polymer systems are particularly 227 
useful for non-structural drug delivery systems70,  as they can be packed into surgical 228 
sites and release drugs during healing before being resorbed into the body. These 229 
polymer systems have been used in applications ranging from advanced wound healing 230 
to the delivery of chemotherapeutics73, 74. In contrast, macro scale polymer-based 231 
hydrogel systems are useful for both surgical and non-surgical drug administration.  A 232 
  
widespread example is hydrogel contact lenses used for ocular drug delivery. These 233 
devices can increase the bioavailability of drugs otherwise limited by burdensome 234 
ocular administration dosing regimens48, 75. They have proven particularly useful for 235 
delivery of medications for eye diseases including glaucoma, and delivery of 236 
antibacterial agents to the eye76-78. In general, hydrogel thickness can be used to control 237 
drug loading, and delivery profiles can be tuned to offer zero-order release kinetics. 238 
Many hydrogel systems are unsuitable for localised ocular delivery applications due to 239 
their limited transparency, stability, and the use of non-biocompatible crosslinking 240 
agents during formation. Drug delivery contact lenses must be designed to possess 241 
luminous transmittance, oxygen permeability, mechanical stability, and 242 
biocompatibility76-79 in addition to their drug loading capacity. These stringent material 243 
requirements highlight the complexities in designing drug delivery systems which 244 
match localised tissue requirements. Next, we discuss advances in macro scale drug 245 
delivery systems which enable a more targeted delivery approach.  246 
Targeted delivery systems 247 
Targeted delivery systems, where a device enables the delivery of a therapeutic to a 248 
target organ or cell based in a different location to the administration site, are relatively 249 
limited in macro scale devices. Due to their scale, macro devices are often too large to 250 
engage with many biological structures and target cells. A notable exception to this is 251 
the use of stimuli responsive macro scale devices for delivery to chemically distinct 252 
regions of the gastrointestinal tract34, 80-82. The chemical environment of the stomach 253 
often poses a challenge to pH sensitive and enzymatically degraded protein and peptide 254 
therapeutics. Drug delivery devices frequently utilise local variations in target tissue pH 255 
to control drug release, with hydrogels sensitive to alkali pH and enteric tablet coatings 256 
facilitating delivery to the intestines. 257 
  
For many other target tissues, macro scale devices are too large to travel through the 258 
vasculature or lymphatic system and move towards target organs. In an alternative 259 
approach, macro devices which can recruit a target cell towards the device to selectively 260 
deliver a therapeutic drug to a target cell type have been developed. These devices have 261 
been trialled in vaccination systems, where chemokines (CXCL12) have been 262 
incorporated into a polymer material to encourage the recruitment of immune cells. 263 
Once the immune cells reach the macro device, they “collect” the drug. In this way, the 264 
macro device can overcome the transport limitation imposed due to its size, and 265 
provides a targeted delivery system to specific cells by recruiting the cell of interest83-85 266 
to the device location. This relatively new concept offers promise for the design of a 267 
range of macro devices which can act in a targeted manner 268 
Summary 269 
Macro scale devices and their component parts can be precisely engineered to allow fine 270 
control over drug dosing schedules, and in some cases, can be coupled with sensor 271 
technology to enable patient specific systemic drug release. The dimensions of most 272 
macro scale devices and their capacity to hold large therapeutic reservoirs renders them 273 
suitable to long term drug delivery. However, these dimensions also limit their 274 
usefulness in targeting smaller biological structures. Although some smaller macro 275 
devices can be surgically inserted into larger target organs (i.e. uterus, large arteries) to 276 
facilitate proximal or localised drug release, devices cannot migrate through the body, 277 
limiting their ability to deliver drugs in a targeted fashion. The advent of new polymer 278 
implants which can directly recruit target cells offers the potential to combine the 279 
intrinsic advantages of macro devices (drug loading capacity, precision engineering, 280 
patient specific stimuli responsive systems) with the targeting advantages usually found 281 
  
in smaller scale systems, and is an exciting future direction for macroscale device 282 
development.  283 
MICRO SCALE DELIVERY SYSTEMS   284 
Devices at the micron scale range from 1-1000µm, allowing them to be introduced 285 
within the body without the need for a major surgical procedure through ingestion 286 
(orally administered osmotic pumps)24, 86, 87, inhalation, and inoculation (microparticles, 287 
microneedles)88-92. Many key biological structures are organised on the micron length 288 
scale, with cells themselves measuring from 5-20 microns in diameter and possessing 289 
cellular substructures on the order of nano- to micro-meters. Several biological transport 290 
networks are also organised on the micro-scale; lymphatic capillaries93, 94 have a 291 
diameter of ~10-60 µm, whilst circulatory vasculature95 measures on the order of 10 292 
mm in arteries and veins to around 1 µm in capillaries. Micro-scale drug delivery 293 
devices therefore offer the unique advantage of being able to interface with organoid, 294 
cellular, and subcellular structures on a comparable length scale to their biological 295 
targets. In addition, they may be able to navigate through the body’s transport networks, 296 
rendering them particularly suitable for localised and targeted delivery systems. Here, 297 
we review a range of micro scale delivery systems with increasing target specificity.  298 
Systemic delivery systems 299 
Microfabricated electromechanical systems (MEMS) 300 
Microfabrication techniques and advances in pump technology have allowed injection 301 
and infusion devices (described earlier in the macro section) to be created on smaller 302 
and smaller length scales. Micro fabricated electromechanical systems (MEMS) offer a 303 
micron sized infusion device that can provide localised fixed rate or variable dose 304 
  
delivery, and recently further miniaturisation of fabrication technologies has encouraged 305 
development of nanoelectromechanical systems96 (NEMS). MEMS systems can deliver 306 
both liquid and solid-phase drug formulations97-104 in a manner analogous to macro 307 
scale infusion pumps. The delivery dose is controlled by an infusion system, which is 308 
either fixed rate (i.e. diffusion-based) or active (i.e. pumped) 9, 97.  In pumped systems, 309 
devices can be either non-mechanical (i.e. electrophoresis, electro osmosis) or 310 
mechanical in nature (piezoelectric, electromagnetic, shape memory alloy), with the 311 
choice of pump system impacting both the delivery dosage schedule and device life 312 
time101-103, 105, 106. For example, non-mechanical pumps usually have a limited flow rate 313 
compared to variable piezoelectric pumps101, 104, 105, 107-110 yet piezoelectric pump 314 
systems often require higher voltage systems and increased operating power, reducing 315 
battery and device lifetime. Although these devices are small enough to be implanted 316 
within the body, they have a reduced reservoir capacity compared to their macro scale 317 
counterparts. To combat the low loading capacity, refillable devices99 are being 318 
developed which enable reservoir replenishment and dose manipulation post-319 
implantation. Due to the placement of these devices within the body, refilling these 320 
systems will likely require an additional surgical procedure, rendering these devices 321 
unsuitable for non-surgical applications.  322 
Microneedles 323 
Microneedle patches have been developed which facilitate drug delivery without 324 
surgical intervention. These consist of an array of high aspect ratio needles90, 91 on the 325 
order of 500-1000 µm in length, which can penetrate the epidermis and reach the 326 
underlying dermal layer. Once they are in contact with this layer, they can be used to 327 
deliver small molecules, proteins, or nucleic acids via hollow, solid, or biodegradable 328 
needles30. The needles are usually made of metal, silica, or polymer composites, and are 329 
  
fabricated through microlithography29, 88-91, 111 using etching, casting, or printing 330 
methods.  The simplest of these systems use solid and porous non-degradable needles 331 
coated with a drug, or biodegradable drug-polymer composite that can dissolve into the 332 
tissue once the microneedles contact the dermal layer. Alternatively, the microneedles 333 
can be uncoated, and removed once they have penetrated the epidermal barrier, 334 
allowing topical application of therapeutics to the area. An alternative system uses 335 
hollow needles coupled to a liquid reservoir, using capillary action to inject liquid into 336 
the dermal layer in an analogous manner to traditional macro needles. In contrast, 337 
biodegradable needle systems can be applied directly to the skin and used to deliver 338 
drugs with a more continuous release profile. By carefully tuning polymer 339 
compositions, these systems can controllably deliver drugs in a single administration 340 
lasting a few seconds, or with a longer kinetic release profile of a few weeks30, 90.  341 
Polymer implants 342 
A range of injectable administration methods have been developed to implant polymer 343 
based micro scaled drug delivery systems. The simplest of these involve micro scaled 344 
polymer masses which are administered using a clinical gauge needle to directly 345 
penetrate the skin barrier, and deposited subcutaneously. A wide range of injectable 346 
polymer compositions have been explored, from early studies using  polylactic acid and 347 
biodegradable polylactide-co-glycolide acid polymer systems, to newer stimuli 348 
responsive copolymer systems, and novel hydrogel systems112.   349 
 Micro scale injectable hydrogels with controlled release properties83, 113-115 have 350 
emerged as promising polymer delivery systems for clinical applications. For example, 351 
shear-thinning hydrogels are particularly well suited to subcutaneous systemic delivery 352 
devices115-117, as they remain liquid during application and solidify on placement post-353 
  
injection. This renders shear thinning hydrogel systems suitable for delivery to a wide 354 
range of target locations, however for longer term release profiles (over 6 months) 355 
multiple hydrogel injections would likely be required in a clinical setting. To prevent 356 
overloading the subcutaneous space with polymer materials, hydrogels with tuneable 357 
degradation rates (matched to the rate of drug release) can ensure polymer residue does 358 
not remain in the body after the therapeutic has been delivered. As an alternative, 359 
refillable drug delivery depots have recently been developed, which aim to overcome 360 
the drug loading limitations inherent in microscopic drug delivery depots. These 361 
systems use “tagged” drugs which can be administered intravenously and migrate 362 
towards the polymer depot118, 119, providing a refillable controlled release depot. 363 
Microparticles 364 
Microparticles typically consist of a degradable, drug loaded microparticle that acts as a 365 
drug delivery depot. These particles can be suspended in saline, and injected 366 
intravenously where, if appropriately sized, they circulate systemically. Microparticles 367 
are typically formed by emulsion or solvent evaporation techniques15, 32, 120-125, 368 
potentially resulting in a loss of potency for sensitive therapeutics after exposure to 369 
organic solvents during the fabrication method. In an alternative approach, ultra-370 
sonication and freezing can be used to generate microparticles with control over 371 
polydispersity[11], reducing the need for organic solvents and maintaining drug 372 
potency. A variety of polymers have been used to fabricate microparticles, and the 373 
choice of polymer directly impacts both the microparticle targeting ability and the 374 
specific release kinetics. For example, PLGA microparticles are FDA approved for 375 
clinical use in a range of applications, including chemotherapeutic drug delivery and 376 
hormone release. Their release profiles can be tuned to continuously deliver therapeutic 377 
load over the course of two days, or for up to eight weeks, depending on the lactide to 378 
  
glycolide ratio126-128 within the polymer. Recently, more advanced microparticles have 379 
been developed which offer a more complex kinetic release profile. These materials 380 
combine several different polymer architectures to offer a single particle that can release 381 
therapeutic load in 2-3 distinct bursts. These systems are likely to prove extremely 382 
useful in vaccine development, where an entire multi-dose vaccination schedule could 383 
be administered systemically in one injection11, 129.  384 
Localised delivery systems 385 
Implantable microchips 386 
As infusion pump and microchip devices have been miniaturised, they have become 387 
increasingly suitable for localised drug delivery applications.  Recently, new MEMS 388 
devices have been developed which offer an implantable “pharmacy-on-a-chip” design, 389 
allowing the delivery of multiple therapeutics, each at a specified time. These devices 390 
can provide precise dosing control through as many as 100 unique reservoirs opened on 391 
the order of microseconds. The first “pharmacy-on-a-chip” devices successfully 392 
completed phase one human clinical trials in 2012, and were used to deliver human 393 
parathyroid hormone fragment86, 130 to eight osteoporotic patients. Taking this 394 
technology further, micron-sized reservoir-based devices holding up to 100 drugs and 395 
drug combinations in a small microchip have been implanted into tumour sites. Due to 396 
their high aspect ratio and small scale, implants can be extracted using a conventional 397 
biopsy needle, and the tissue can be examined to determine tumour regression in 398 
response to each of the therapeutic drugs and drug combinations tested. In this way, 399 
surgeons and oncologists can develop a personalised drug treatment plan for cancer 400 
patients based on positive responses to specific drug combination therapies131, 132, tested 401 
using the microchip.  402 
  
Controlled polymer architecture 403 
Polymers can be modified to display controlled topographical and physical features, 404 
enabling delivery of therapeutics to a specific biological target organ. For example, the 405 
Nektar aerosolised inhaler based systems deliver microparticles containing a range of 406 
therapeutics, and uses microparticles with a reduced density to aid pulmonary particle 407 
delivery133. Microparticle geometry has also been shown to directly impact cellular 408 
uptake, with both particle size and shape134-138 playing an important role in the response 409 
of specific tissues and cells. Given the importance of the three dimensional structure to 410 
cellular interactions, shape memory polymers are being developed that can be injected 411 
into a target organ using a syringe, and then resume a specific 2D or 3D shape on 412 
reaching 37°C in the body. One example of these systems involves bio-adhesive shape 413 
memory hydrogel sheets, which provide an easily applied, injectable patch drug 414 
delivery device for local drug administration72, 139-142.  415 
Targeted delivery systems  416 
Ligand targeting 417 
The identification of organ and cell specific ligands has facilitated targeted delivery of 418 
micro scale systems. This is often accomplished using conjugation strategies which link 419 
targeting ligands onto polymers. Ligand conjugated polymers can be used to form drug 420 
delivery microparticles, which can be formulated to encapsulate a range of therapeutic 421 
cargo including proteins, small molecules, and cytokines within a ligand decorated 422 
polymer shell17, 143. Conjugation of specific ligands can also alter the systemic 423 
circulation time; for example the inclusion of a polyethylene glycol (PEG) moiety is 424 
thought to prevent binding and uptake of microparticles by non-targeted cell types. The 425 
inclusion of specific ligands facilitates microparticle binding to specific cells and tissues 426 
  
presenting the receptor for the attached ligand. These systems have proven particularly 427 
useful for targeting the liver though the ASGPR1 receptor144, 145, or targeting 428 
systemically circulating dendritic cells146, 147. As ligands of other target organs are 429 
identified, this method will enable more specific targeting.  430 
Microbubbles 431 
In an alternative approach, smaller, drug loaded microbubbles have been injected 432 
systemically. The application of ultrasound (which bursts these bubbles) can be used to 433 
target drug release to a specific therapeutic area. This emerging technology makes use 434 
of clinically available imaging facilities located in hospitals and clinics to induce 435 
controlled release in target biological structures. The technique has proven popular in 436 
delivering drugs to larger target organs, such as the kidney148-150. The development of 437 
ultrasound mediated drug deliver follows previous discoveries that traditional delivery 438 
through topical administration to the skin, gastrointestinal tract and mucus membranes 439 
is enhanced with simultaneous application of an ultrasound probe151, 152.  440 
Summary  441 
Micro scale systems offer a robust tool to facilitate drug delivery in systemic, localised, 442 
and targeted fashions. Whilst macro scale devices can offer controlled release for 443 
durations of months to years, micro systems have limited reservoir and loading 444 
capacity, usually limiting drug delivery to weeks and months. There are also limited 445 
examples of systems with programmed release profiles, as the majority of the drug 446 
delivery systems rely on diffusion and biodegradation to provide a continuous and fixed 447 
rate delivery. Recently, pulsatile hydrogel release systems, pulsatile microparticles, and 448 
stimuli responsive drug delivery approaches have been developed which offer the 449 
promise of greater control over complex dosing schedules. Although micro systems are 450 
  
limited by therapeutic reservoir and release profiles, they excel in providing localised 451 
and targeted drug delivery. Their small scale enables implantation into key organs, and 452 
microparticles and microbubbles can travel through the vasculature to enable both 453 
systemic and more targeted delivery. Poorly vascularised tissues, and those isolated by 454 
complex physiological barriers such as the blood-brain barrier, remain difficult to target. 455 
As new approaches to crossing physiological barriers are identified, micro scale systems 456 
will play an increasingly important role in targeted delivery.   457 
NANO SCALE DELIVERY SYSTEMS  458 
Nanoscale systems are generally defined as being of the order of between 1 to 459 
100 nm (ISO/TS 80004-1:2015), however in practice can range from 1 to 1000 nm153.  460 
Nanotechnology can be used to improve the pharmacokinetic properties of traditional 461 
pharmaceuticals, increase circulation time, solubility, and enhance delivery into 462 
difficult-to-access tissues.  In addition, nanostructures below 200 nm can undergo 463 
uptake in various cell types and avoid clearance by phagocytosis154, making nanoscale 464 
systems particularly promising for targeted intra-cellular delivery of a variety of 465 
therapeutic cargo. This section will provide an overview of recent advances in 466 
nanotechnology for drug delivery, and identify remaining challenges. 467 
Systemic delivery systems 468 
Nanoparticles 469 
Nanoparticle systems enable the systemic delivery of sensitive or unstable therapeutics 470 
by protecting them against degradation, extending circulation time, and facilitating 471 
delivery across biological barriers that would normally be prevented due to 472 
hydrophilicity, size or charge [9, 10]. Re-formulating existing drugs into nanoparticle 473 
  
delivery systems can reduce toxicity, and nanoparticles can be formulated using a 474 
variety of materials including lipids, polymers and peptides. Nanoparticle formulations 475 
can also be used to deliver sensitive cargo at risk of degradation from ubiquitous 476 
nucleases in vivo, such as nucleic acids. Systemic nanoparticle mediated delivery has 477 
been demonstrated for mRNA155, and localized delivery of DNA has been demonstrated 478 
following topical application of DNA nanoparticles to the skin156 in patients with 479 
epidermolysis bullosa. 480 
To improve solubility, drugs are often encapsulated inside micelle carriers, or 481 
conjugated to water soluble polymers. Liposome-based carriers were first described in 482 
the 1960s and are amongst the most well established nano-carriers for systemic delivery 483 
157. They have been widely used to improve aqueous solubility of hydrophobic drugs, 484 
illustrated by the antifungal amphotericin B, which is insoluble at physiological pH and 485 
also highly toxic. The liposomal formulation of this drug, AmBisome®, can be 486 
administered systemically with dramatically reduced toxicity158-160.  487 
Synthetic conjugates have also been used to formulate drug delivery nanoparticles, and 488 
inclusion of water soluble polymers, such as polyethylene glycol, can aid systemic 489 
solubility without the inclusion of dose-limiting solvents.  Paclitaxel is an example of a 490 
poorly water-soluble drug that has been formulated within degradable polylactide-491 
polyethylene glycol block co-polymers, allowing better delivery through nanoscale drug 492 
delivery micelles (Genexol-PM). These micellar nanoparticle formulations can also 493 
enhance transdermal drug delivery161-163, and have been used to deliver hormones such 494 
as estradiol via topical application.The incorporation of polyethylene glycol (PEG) into 495 
these nanoparticle systems can increase particle stability164-166, reduce protein 496 
adsorption (opsonization), and prevent subsequent phagocytic clearance. For example, 497 
PEGylated liposomal doxorubicin formulations have been shown to extend circulation 498 
  
times164, 167 when compared to uncoated liposomes, or free doxorubicin. However, 499 
studies have indicated that repeated administration of PEGylated formulations can lead 500 
to an increased clearance rate of subsequent doses of PEGylated liposomes. This is 501 
likely due to IgM antibodies raised after first exposure 164 or pre-existing IgG antibodies 502 
to PEG. 168  503 
Nanowires, nanoneedles and nanotubes 504 
High-aspect-ratio nanoscale systems169-171 such as nanowires, nanoneedles and 505 
nanotubes have been used to deliver a wide variety of biomolecules, and can be 506 
combined with macro and micro systems to enhance drug delivery technologies. For 507 
example, micron scaled drug delivery particles have been coated with nanowires which 508 
enhance retention in the mucosal tract. This strategy enables prolonged retention to 509 
mucosal epithelial tissue172, facilitating enhanced drug delivery and limiting clearance. 510 
In addition, nano scale needles (nanoneedles), wires, and tubes can be loaded directly 511 
with drugs for intracellular drug delivery. Biodegradable silicon nanoneedles grafted 512 
onto micron sized patches have been used for the intra-cellular delivery of VEGF DNA 513 
to localised regions of skin and exposed muscle169, where they are able to enhance 514 
neovascularization compared to delivery of naked DNA. Recently, more sophisticated 515 
systems have been developed which can release cargo in response to specific stimuli29, 516 
92, including changes in pH and temperature, and the presence of specific enzymes. 517 
High-aspect delivery systems are typically silicon-based, however alternative materials 518 
(such as carbon nanotube based drug reservoirs173-176) are currently being developed. 519 
These material systems will need to meet stringent nano scale safety and toxicity 520 
requirements before widespread clinical use.   521 
  
Nanogels 522 
Nanoscale hydrogels (nanogels) broadly consist of crosslinked polymeric particles 523 
which can be synthesized using a range of synthetic and naturally derived materials 524 
including polyacrylamides, polydimethylsiloxane, and chitosan166, 177-180. Nanogels offer 525 
a large surface area for bioconjugation, and as for the microgel systems described 526 
earlier, cross-linking can be used to fine tune drug delivery release kinetics for the 527 
delivery of hydrophobic, hydrophilic and charged solutes. Nanogels have been used for 528 
both targeted intracellular delivery and systemic delivery. These systems have recently 529 
been applied to intra-nasal vaccine delivery, where they can be retained in nasal mucosa 530 
to generate systemic immunity as well as local mucosal immunity181, 182.   531 
Localised delivery systems 532 
Stimuli responsive nanosystems  533 
In an effort to move towards systems with spatio-temporal control of drug delivery, a 534 
number of nanosystems have been developed which can be triggered to release cargo by 535 
exposure to external stimuli such as heat, light and ultrasound. Ultrasound has been 536 
utilized to increase transdermal delivery of a variety of nanoparticles through the skin29, 537 
149, 150, whilst heat and light sensitive nanosystems have enabled delivery to deeper 538 
tissues. For example, thermosensitive lipids that have transition temperatures between 539 
40-45°C can be used to formulate liposomes that become unstable and release cargo 540 
once exposed to this temperature. ThermoDox® is a temperature-sensitive doxorubicin-541 
PEGylated liposome that is systemically delivered but releases cargo in regions where 542 
local temperatures are elevated to 40 °C by application of radiofrequency. The thermo-543 
responsive formulation was shown to increase local concentration of the drug several 544 
folds higher in the radiofrequency treatment area compared to intravenously 545 
  
administered doxorubicin, and compared to non-thermosensitive liposomal formulations 546 
of doxorubicin183. 547 
Alternatively, light has been used as an external stimulus for photodynamic 548 
therapies. Visudyne® is a liposomal formulation of verteporfin184, 185 used to treat 549 
ocular conditions. It is systemically administered but only exerts its toxic effects when 550 
exposed to light. When light is applied to the eye, this formulation can be used to treat 551 
ocular neovascularization due to diseases such as age-related macular degeneration. For 552 
these treatments to be successful, stimuli must be able to penetrate to the target tissue to 553 
facilitate drug release. This renders tissues closer to the surface more amenable to these 554 
therapies; for deeper structures alternative targeted delivery systems are required.  555 
Targeted delivery systems  556 
Site-specific accumulation  557 
Systemically delivered nanoparticle systems may accumulate in organs such as the 558 
liver, lung and in tumors. This site-specific accumulation after systemic administration 559 
has been observed using nanocarriers where there is no specific targeting moiety. 560 
Nanoparticles that tend to accumulate at tumor sites are thought to be subject to the 561 
enhanced permeability and retention186 (EPR) effect. Nanoparticles are small enough to 562 
traverse through the leaky blood-tumor barrier resulting in accumulation and therefore 563 
enhanced drug delivery to the tumor site. Lung accumulation is thought to be due to the 564 
cationic nature of nanoparticles leading blood component aggregation and accumulation 565 
in pulmonary vasculature.187, 188 566 
Selective biodistribution has also been attributed to in vivo post-modification of 567 
nanoparticles, where particular apolipoproteins are preferentially adsorbed onto the 568 
nanoparticle, and can facilitate trafficking to, and enhance retention in, the 569 
  
corresponding organ. In one example, polysorbate 80 modified polybutylcyanoacrylate 570 
nanoparticles were used to deliver doxorubicin to the brain. Doxorubicin does not cross 571 
the blood brain barrier alone, but when delivered as a nanoparticle formulation, delivery 572 
to the brain was achieved189 and found to be due to adsorption of apolipoprotein onto 573 
the polymer nanoparticles. Similarly, lipid nanoparticles carrying nucleic acids were 574 
shown to accumulate in the liver after adsorption of apolipoprotein E190, 191. These 575 
examples demonstrate that nanoparticle design must consider factors such as particle 576 
size, charge and shape170, 192, which can influence tissue accumulation and therefore 577 
targeting efficacy.   578 
Receptor-mediated targeting 579 
In a similar manner to microparticle based delivery, nanoparticles can be formulated 580 
with protein and ligand tags to enable selective delivery.  Identifying specific receptor 581 
ligand pairs which enable cell selective delivery is a topic of great interest. To reduce 582 
phagocytosis and enhance therapeutic efficacy, nanosystems can be conjugated with 583 
“self” peptides such as CD47193 which act as a “don’t eat me” marker. For tumor 584 
targeting, nanoparticles can be decorated with ligands that target receptors that are 585 
overexpressed in cancer cells, such as the transferrin receptor194. Protein and antibody 586 
tagging can also facilitate organ and cellular targeting; HER2 antibodies have been 587 
conjugated to liposomal doxorubicin165 to mediate targeted binding in breast cancer. 588 
Antibody presentation on nanoparticles can also increase cellular particle uptake; when 589 
trastuzumab and rituximab were bound to PLA particles, particle uptake was increased 590 
six-fold compared with PLA particles lacking targeting molecules195. In an alternative 591 
strategy, Abraxane, an albumin bound nanoparticle formulation of paclitaxel, is thought 592 
to undergo an albumin-receptor (gp60) mediated endothelial transcytosis196-198, enabling 593 
the drug to pass through endothelial cell walls in tumor micro vessels to achieve 594 
  
enhanced intra-tumoral concentrations and anti-tumor activity.   595 
In addition to targeting specific cells, nanocarriers that contain cargo must also 596 
efficiently enter cells to deliver the therapeutic component. Particle shape, size, and 597 
composition can all affect penetration efficacy, and coating the nanoparticle with cell 598 
penetrating peptides is proving a promising strategy. By screening a library of cell 599 
penetrating peptides (CPP) using a high throughput strategy, three human peptides were 600 
identified which improved in vivo delivery when conjugated to lipid-like 601 
nanoparticles199. As the mechanism for cellular entry and endosomal escape become 602 
better understood, new ligands will be identified to enhance these processes and 603 
enhance intracellular targeting with increased specificity and efficiency. 604 
Summary 605 
Nano based systems are an enabling technology for the delivery of traditional drugs and 606 
novel therapies such as nucleic acid based drugs. Nanoparticles can be used to optimize 607 
the pharmacokinetics of conventional therapeutics, and offer a promising platform for 608 
targeting specific cells and organelles by manipulating biological pathways such as 609 
endocytosis and ligand targeting to gain cellular entry. Due to their small scale, drug 610 
loading and precision engineering is challenging, rendering current nanoscale systems 611 
less suited for the continued or controlled release of therapeutic loads. Additionally, the 612 
development of safe and effective nanoscale materials presents a significant hurdle for 613 
clinical translation.   614 
CONCLUSIONS  615 
Modern drug therapies include small molecules, proteins, and genetic 616 
engineering based strategies. These therapies often have precise biological therapeutic 617 
targets, and are most effective when delivered with specific dosing regimens. The need 618 
  
to combine targeted delivery and dosing in smaller and smaller scale systems has driven 619 
the miniaturisation of drug delivery devices from the macro to micro to the nano scale. 620 
We have reviewed a range of devices and described their ability to controllably deliver 621 
biomolecules, summarised in Table 1 and Figure 4. In general, macro devices offer 622 
precisely engineered systems which can provide systemic and localised drug delivery 623 
over a period of several years. Devices have a defined lifetime, usually limited by 624 
battery power and reservoir capacity, before they need to be surgically replaced. In 625 
some cases, precision engineering and the incorporation of wireless sensors for on-626 
demand sensing has enabled patient specific drug delivery, most commonly applied to 627 
insulin therapies.  As the length scale of these devices is reduced to smaller macro 628 
devices, they can be surgically implanted into additional target organs to enable 629 
localised therapeutic delivery, however their scale limits their ability to target smaller 630 
biological structures. In a smart workaround, cell specific delivery can be achieved 631 
using macro scale polymer implants that recruit desired cells for targeted delivery, and 632 
when coupled with refillable drug depots this will provide an exciting future direction 633 
for cell specific delivery.  634 
In contrast, micro and nano systems can often be coupled with targeting ligands and can 635 
travel through the vasculature and lymphatic systems to reach specific cell targets. 636 
Several of these systems can undergo burst release in response to external stimuli such 637 
as light, heat, or ultrasound. However, there are limited examples of these systems being 638 
able to intrinsically facilitate controlled dosing schedules. Notable exceptions are burst 639 
release polymer particles which offer a single administration of an entire dosing 640 
schedule, and stimuli responsive nanoneedle delivery systems which use cleavable 641 
linkers to deliver therapeutics in response to target enzyme expression. These systems 642 
straddle the boundary between sensing and drug delivery and offer an exciting direction 643 
  
for responsive drug delivery therapies. A major limitation to micro and nano scale 644 
systems is the limited therapeutic load these systems can carry, limiting the duration of 645 
controlled release to between hours and, at most, a few months. This suggests micro- 646 
and nano- scale systems are best suited to short term delivery of up to 3 months, or the 647 
targeted delivery of curative and preventative therapeutics that can be administered with 648 
a single application.   649 
Moving forwards, next generation devices will focus on increasing the efficacy of 650 
therapeutic delivery at smaller and smaller length scales. As mechanisms of 651 
nanoparticle cellular entry and endosomal escape are elucidated, nanoscale systems with 652 
greater delivery efficacy and therapeutic effect will be developed. Additionally, the 653 
development of stimuli responsive polymer systems will enable on-demand and patient-654 
specific delivery systems to be developed in response to specific cues. Future devices 655 
will combine the advantages of macro scale delivery systems with the precise targeting 656 
capabilities of devices on the nano scale.  657 
  658 
  
FIGURES AND TABLES:  659 
FIGURE 1: Length scales in drug delivery An overview of the biological length 660 
scales important in drug delivery, including target organs, biological barriers and sub-661 
cellular structure of interest.  662 
 663 
  664 
  
FIGURE 2: Miniaturisation of controlled dosing pump systems Infusion based 665 
devices have progressed rapidly from macroscale implantable pump systems able to 666 
deliver single therapeutics (A) to micro scaled pumps capable of delivering over 100 667 
individual doses (B). Figures were adapted from the following references with 668 
permission: A- Adapted with permission from Nature Biotechnology 200 © 2003; B- 669 
Reprinted with permission from Science Translational Medicine 130 © 2012. 670 
 671 
  672 
  
FIGURE 3: Polymer based drug delivery systems across length scales Polymer 673 
based drug delivery systems offer extremely versatile morphologies for drug delivery 674 
applications across several orders of magnitude. On the macro scale, flexible polymers 675 
have been folded into capsules small enough to swallow. (A) Precision engineering has 676 
enabled macro scale stents which possess micron scale features. These features are often 677 
made of, or coated in, biodegradable polymer substrates (B) providing both rigidity and 678 
drug eluting capabilities. (C) Polymer nanoneedles can be fabricated with a variety of 679 
aspect ratios to penetrate cells for nucleic acid drug delivery.  Figures were adapted 680 
from the following references with permission: A- Reprinted with permission from  681 
Science Translational Medicine 201 © 2016.  B- Reprinted with permission from the 682 
Journal of Interventional Cardiology 202 © 2004.  C- Reprinted by permission from 683 
Macmillan Publishers Ltd [165] © 2015.   684 
 685 
  686 
  
FIGURE 4: Overview of drug delivery systems by length scale A comparison 687 
between drug delivery strategies across length scales, illustrated by material delivery 688 
class, scale and the targeting ability to each therapy. Due to their scale, there are few 689 
examples of targeted macro scale drug delivery systems.  690 
  691 
  
TABLE 1: Considerations in drug delivery device design The table provides an 692 
extension to Figure 4, and overview of the main considerations in drug delivery device 693 
design according to device scale. Types of device, typical therapeutics, targeting ability 694 
and typical delivery profiles are indicated for highlighted delivery systems.  695 
Scale 
 
Device  
(administration route) 
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Macro Ingestible devices 
(ingestion) 
Peptides, Proteins, Small 
molecules 
         
Skin patches Peptides, Proteins, small 
molecules 
         
Polymer implants Peptides, Proteins, Small 
Molecules 
         
Pumps Proteins, Small Molecules          
Micro Microneedles Peptides, Proteins, Small 
Molecules, nucleic acids 
         
Microparticles Proteins, Small Molecules          
Polymer implants Proteins, Small Molecules          
Microbubbles Proteins          
Nano Nanoneedles, tubes and 
wires 
Peptides, Proteins, nucleic 
acids, small molecules 
         
Nanogels Peptides, proteins, small 
molecules  
         
Nanoparticles Peptides, Proteins, nucleic 
acids, small molecules, 
nucleic acids 
         
 696 
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